Table 1.
Demographics and clinical features of patients prescribed on angiotensin receptor neprilysin inhibitors.
| Clinical Parameters | Mean ± SD/percentage (n = 589) |
|---|---|
| Age - years | 68 ± 20.5 |
| Female Sex – no. (%) | 37.6 |
| Weight | 68 ± 35.6 kg |
| BMI$ | 34 ± 12.4 kg/m2 |
| NYHA class# | |
| II | 32% |
| III | 40% |
| IV | 28% |
| LVEF | 18–40% (32 ± 4) |
| Risk factors | |
| Type II Diabetes Mellitus | 38.9% |
| Hypertension | 42.4% |
| Dyslipidemia | 68.8% |
| Active Smoker | 12.2% |
| Symptoms | |
| Breathlessness | 98% |
| Paroxysmal Nocturnal dyspnea | 78% |
| Orthopnea | 36% |
| Easy fatiguability | 52% |
| Chest pain | 22% |
| HF etiology | |
| Ischemic | 45% |
| Non-ischemic | 54% |
| Unknown | 1% |
| Cardiac rhythm | |
| Sinus rhythm | 84% |
| Atrial fibrillation | 14% |
| Atrial Flutter | 2% |
| Medical History | |
| Hospitalization for Heart Failure | 75.4% |
| Myocardial infarction | 44.2% |
| Stroke | 11.7% |
| Peripheral vascular disease | 4.5% |
Plus-minus values are means ± SD. $The body-mass index is the weight in kilograms divided by the square of the height in meters. #The data for New York Heart Association (NYHA) class reflect the status of patients at the time start of SGLT2i, dapagliflozin. Patients were required to have at least NYHA class II symptoms at the screening. Body mass index = BMI; New York Heart Association = NYHA; Left ventricular ejection fraction = LVEF; Implantable cardioverter-defibrillator = ICD; Cardiac resynchronization therapy pacemaker = CRT-P; Cardiac resynchronization therapy with defibrillator = CRT- D.